Brainstorm Cell Therapeut... (BCLI)
NASDAQ: BCLI
· Real-Time Price · USD
1.22
0.03 (2.52%)
At close: Jun 24, 2025, 3:59 PM
1.24
1.44%
After-hours: Jun 24, 2025, 07:59 PM EDT
2.52% (1D)
| Bid | 1.2 |
| Market Cap | 9.7M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.62M |
| EPS (ttm) | -2.01 |
| PE Ratio (ttm) | -0.61 |
| Forward PE | -1.32 |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 370,890 |
| Avg. Volume (20D) | 1,343,516 |
| Open | 1.17 |
| Previous Close | 1.19 |
| Day's Range | 1.16 - 1.23 |
| 52-Week Range | 0.72 - 6.60 |
| Beta | 0.21 |
About BCLI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCLI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCLI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+3.03%
BrainStorm Cell Therapeutics shares are trading hi...
Unlock content with
Pro Subscription
7 months ago
+1.67%
Brainstorm Cell Therapeutics and Pluri shares are trading higher after the companies entered into a memorandum of understanding to manufacture NurOwn for a Phase 3b trial in amyotrophic lateral sclerosis.
1 month ago · seekingalpha.com
Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call TranscriptBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Joyce Lonergan - Investor Relations, LifeSci Advisors Chaim Lebovits - Pr...
2 months ago · seekingalpha.com
Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call TranscriptBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Michael Wood - Investor Relations Chaim Lebovits - President & Chief Ex...